The European Microbiome Innovation for Health (EMIH) and the Microbiome Therapeutics Innovation Group (MTIG) have agreed to collaborate to advance the development of microbiome-based products and drugs, broadening patient access to approved microbiome therapeutics.
A key priority of the agreement is harmonising regulatory frameworks from different regions, so that a broad range of perspectives are collated. The parties highlighted this will help to generate “a more cohesive approach” to finding the resolutions for policy and regulatory challenges faced by developers of microbiome therapeutic drugs.
Improving availability of microbiome therapeutics
“MTIG’s founding principal is to accelerate patients’ access to innovative microbiome therapeutics through our communal efforts,” explained Dr Nikole Kimes, Chairman of MTIG and CEO of microbiome therapy company Siolta Therapeutics.
“By joining forces with MTIG, we will accelerate the development and delivery of microbiome therapies, ensuring that groundbreaking treatments reach those who need them most, swiftly and safely,” commented Hervé Affagard, President of EMIH and CEO and co-founder of MaaT Pharma.
By joining forces with MTIG, we will accelerate the development and delivery of microbiome therapies, ensuring that groundbreaking treatments reach those who need them most, swiftly and safely”
Currently, MTIG comprises of the following companies focusing on microbiome therapeutics:
- BiomeSense
- Biose Industrie
- Freya Biosciences
- MaaT Pharmaceutical
- Microba Life Sciences
- Rebiotix Inc., a Ferring Company
- Seres Therapeutics
- Siolta Therapeutics
- Vedanta Biosciences.
Read: EPR’s article series on microbiome therapeutics
Furthermore, the EMIH, an independent coalition within the EU, UK and Switzerland, contains member companies including: Bioaster, Biocodex, BioGaia, Biofortis, Biose Industrie, Eligo Bioscience, GMT Science, INRAe, Lallemand Health Solutions, Life Avocats, Enosis Santé, EnteroBiotix, Pelican Health, MaaT Pharma, mbiomics, Microbiotica, Microbiome Foundation, MRM Health, Nexbiome, Novobiome, Seventure Partners and SwipeBiome.
EMIH noted that their membership is open to pharma and biotech companies looking to obtain European regulatory approvals for microbiome bioproductions, diagnostics as well as medical devices.
CRISPR-based microbial gene therapy delivers promise
LBP-immunotherapy could benefit oncology patients
The post New collaboration to boost access to innovative microbiome therapies appeared first on European Pharmaceutical Review.
